We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
5uf9
From Proteopedia
(Difference between revisions)
m (Protected "5uf9" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Estrogen Receptor Alpha Ligand Binding Domain in Complex with OP1156== | |
| - | + | <StructureSection load='5uf9' size='340' side='right' caption='[[5uf9]], [[Resolution|resolution]] 2.00Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[5uf9]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5UF9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5UF9 FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=85M:(2R,3S,4R)-3-(4-hydroxyphenyl)-4-methyl-2-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-3,4-dihydro-2H-1-benzopyran-7-ol'>85M</scene></td></tr> | |
| - | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5uf9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5uf9 OCA], [http://pdbe.org/5uf9 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5uf9 RCSB], [http://www.ebi.ac.uk/pdbsum/5uf9 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5uf9 ProSAT]</span></td></tr> |
| + | </table> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/ESR1_HUMAN ESR1_HUMAN]] Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Isoform 3 can bind to ERE and inhibit isoform 1.<ref>PMID:7651415</ref> <ref>PMID:10970861</ref> <ref>PMID:9328340</ref> <ref>PMID:10681512</ref> <ref>PMID:10816575</ref> <ref>PMID:11477071</ref> <ref>PMID:11682626</ref> <ref>PMID:15078875</ref> <ref>PMID:16043358</ref> <ref>PMID:15891768</ref> <ref>PMID:16684779</ref> <ref>PMID:18247370</ref> <ref>PMID:17932106</ref> <ref>PMID:19350539</ref> <ref>PMID:20705611</ref> <ref>PMID:21937726</ref> <ref>PMID:21330404</ref> <ref>PMID:22083956</ref> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Fanning, S W]] | ||
| + | [[Category: Fowler, C E]] | ||
| + | [[Category: Green, B D]] | ||
| + | [[Category: Greene, G L]] | ||
| + | [[Category: Harmon, C L]] | ||
| + | [[Category: Hodges-Gallager, L]] | ||
| + | [[Category: Kushner, P J]] | ||
| + | [[Category: Myles, D C]] | ||
| + | [[Category: Sun, R]] | ||
| + | [[Category: Acquired antiestrogen resistance]] | ||
| + | [[Category: Antiestrogen]] | ||
| + | [[Category: Breast cancer]] | ||
| + | [[Category: Endocrine therapy]] | ||
| + | [[Category: Estrogen receptor alpha]] | ||
| + | [[Category: Nuclear hormone receptor]] | ||
| + | [[Category: Selective estrogen receptor degrader]] | ||
| + | [[Category: Steroid receptor]] | ||
| + | [[Category: Transcription]] | ||
Revision as of 08:27, 10 January 2018
Estrogen Receptor Alpha Ligand Binding Domain in Complex with OP1156
| |||||||||||
Categories: Fanning, S W | Fowler, C E | Green, B D | Greene, G L | Harmon, C L | Hodges-Gallager, L | Kushner, P J | Myles, D C | Sun, R | Acquired antiestrogen resistance | Antiestrogen | Breast cancer | Endocrine therapy | Estrogen receptor alpha | Nuclear hormone receptor | Selective estrogen receptor degrader | Steroid receptor | Transcription
